| PTLE 0.282 51.53% | SOXS 3.65 11.56% | MSPR 0.664 27.57% | SCNX 0.8182 15.35% | NVDA 198.69 -3.96% | SQQQ 13.79 6.16% | ORIS 0.1603 -0.12% | BYND 1.33 -4.32% | PFE 24.3 -1.46% | HTZ 6.73 36.23% | PLTR 190.74 -7.94% | TSLL 20.34 -10.16% | ETHA 24.28 -10.37% | ASST 1.25 -1.57% | IBIT 57.18 -5.53% | GRAB 5.785 -4.70% | INTC 37.03 -6.25% | PLUG 2.52 -8.36% | ONDS 5.96 -3.09% | OPEN 6.92 -8.83% | CHR 0.136 8.11% | FGL 0.5165 26.94% | DNN 2.74 -6.00% | TSLA 444.26 -5.15% | WTO 0.0497 -6.23% | CAPT 0.6615 31.77% | NFE 1.35 14.41% | SOXL 42.8 -11.90% | BITF 3.84 -6.57% | ETHD 5.26 20.92% | T 24.44 -0.37% | EPWK 0.0748 3.60% | F 12.79 -1.69% | SPY 675.24 -1.19% | SOFI 29.37 -4.11% | KVUE 15.97 -1.05% | ACHR 9.56 -8.25% | CIFR 22.51 -1.10% | QQQ 619.25 -2.03% | HIMS 42.79 -3.60% | GPUS 0.3494 -7.03% | TQQQ 111.08 -6.12% | LQD 110.68 0.14% | BTBT 3.18 -7.02% | AAL 12.65 -5.17% | TZA 8.21 5.26% | BURU 0.29 -7.91% | NCLH 18.79 -15.28% | RGTI 35.18 -10.07% | BTG 4 -5.77%

Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Financial Performance

Lantheus Holdings, Inc. (NASDAQ:LNTH) is a company that specializes in the development and commercialization of innovative diagnostic imaging agents and products. These products are primarily used in the diagnosis and treatment of cardiovascular and other diseases. Lantheus competes with other companies in the medical and pharmaceutical sectors, such as ShockWave Medical, Inc., Medpace Holdings, Inc., LivaNova PLC, Apellis Pharmaceuticals, Inc., and Natera, Inc.

Lantheus Holdings boasts a Return on Invested Capital (ROIC) of 17.16% and a Weighted Average Cost of Capital (WACC) of 4.55%. This results in a ROIC to WACC ratio of 3.77, indicating that the company is generating returns well above its cost of capital. This is a positive indicator for investors, as it suggests efficient capital utilization and profitability.

In comparison, ShockWave Medical, Inc. has a ROIC of 5.29% and a WACC of 8.26%, resulting in a ROIC to WACC ratio of 0.64. This suggests that ShockWave is not generating returns above its cost of capital, which may be a concern for investors. On the other hand, Medpace Holdings, Inc. stands out with a ROIC of 114.80% and a WACC of 10.46%, leading to a ROIC to WACC ratio of 10.98. This indicates exceptional efficiency in generating returns, making Medpace an attractive investment opportunity.

LivaNova PLC has a ROIC of 11.60% and a WACC of 7.90%, resulting in a ROIC to WACC ratio of 1.47. While this is above 1, it is not as high as Lantheus or Medpace, suggesting moderate efficiency in capital utilization. Apellis Pharmaceuticals, Inc. and Natera, Inc. both have negative ROIC to WACC ratios of -4.02 and -1.30, respectively. This indicates that these companies are not generating returns above their cost of capital, which may be a red flag for potential investors.

Overall, Lantheus Holdings, Inc. demonstrates strong performance with its ROIC to WACC ratio of 3.77, indicating efficient capital utilization. However, Medpace Holdings, Inc. leads the peer group with a significantly higher ratio, suggesting superior capital efficiency and growth potential. Investors may consider these metrics when evaluating investment opportunities within this sector.

Published on: August 8, 2025